

Laurent Arnaud

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6261051/publications.pdf>

Version: 2024-02-01

112
papers

5,570
citations

81839

39
h-index

88593

70
g-index

115
all docs

115
docs citations

115
times ranked

5871
citing authors

#	ARTICLE	IF	CITATIONS
1	Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry"™. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e113-e113.	0.5	3
2	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2023, 75, 998-1006.	1.5	7
3	The history of lupus throughout the ages. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1361-1369.	0.6	12
4	Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e79-e79.	0.5	4
5	Physician Global Assessment as a Disease Activity Measure for Relapsing Polychondritis. <i>Arthritis Care and Research</i> , 2022, 74, 1269-1276.	1.5	5
6	Significance of Sjögren's syndrome and anti-cN1A antibody in myositis patients. <i>Rheumatology</i> , 2022, 61, 756-763.	0.9	8
7	Discordance in patient and physician global assessment in relapsing polychondritis. <i>Rheumatology</i> , 2022, 61, 2025-2033.	0.9	1
8	Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab. <i>Lancet Rheumatology</i> , The, 2022, 4, e13-e16.	2.2	40
9	Controversies in Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e651-e658.	0.5	1
10	Difficulties and Psychological Impact of the SARS-CoV-2 Pandemic in Patients with Systemic Lupus Erythematosus: A Nationwide Patient Association Study. <i>Healthcare (Switzerland)</i> , 2022, 10, 330.	1.0	6
11	Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2110730.	1.2	52
12	Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries. <i>Lancet Rheumatology</i> , The, 2022, 4, e160-e163.	2.2	12
13	Prevalence and factors associated with long-term remission in cutaneous lupus: A longitudinal cohort study of 141 cases. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 323-332.	0.6	4
14	Treatment of relapsing polychondritis: a systematic review.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
15	Physician Global Assessment International Standardisation CONsensus in Systemic Lupus Erythematosus: the PISCOS study. <i>Lancet Rheumatology</i> , The, 2022, 4, e441-e449.	2.2	17
16	Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study. <i>Lupus Science and Medicine</i> , 2022, 9, e000700.	1.1	1
17	Patterns of fatigue and association with disease activity and clinical manifestations in systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 2672-2677.	0.9	19
18	Characterization of drug-induced cutaneous lupus: Analysis of 1994 cases using the WHO pharmacovigilance database. <i>Autoimmunity Reviews</i> , 2021, 20, 102705.	2.5	7

#	ARTICLE	IF	CITATIONS
19	Systemic sclerosis overlap and non-overlap syndromes share clinical characteristics but differ in prognosis and treatments. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 36-42.	1.6	16
20	The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. <i>Nature Reviews Rheumatology</i> , 2021, 17, 177-184.	3.5	35
21	Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110025.	1.2	5
22	Atrial fibrillation in patients treated with intravenous zoledronic or pamidronic acid: a pharmacoepidemiological study. <i>European Journal of Endocrinology</i> , 2021, 184, 437-444.	1.9	6
23	Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases. <i>Lancet Rheumatology, The</i> , 2021, 3, e243-e245.	2.2	97
24	Prevalence of Antineutrophil Cytoplasmic Antibody-associated Vasculitis and Spatial Association With Quarries in a Region of Northeastern France: A Capture-Recapture and Geospatial Analysis. <i>Arthritis and Rheumatology</i> , 2021, 73, 2078-2085.	2.9	14
25	Living with systemic lupus erythematosus in 2020: a European patient survey. <i>Lupus Science and Medicine</i> , 2021, 8, e000469.	1.1	27
26	Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?. <i>Joint Bone Spine</i> , 2021, 88, 105143.	0.8	18
27	Cluster analysis reveals three main patterns of beliefs and intention with respect to SARS-CoV-2 vaccination in patients with autoimmune and inflammatory diseases. <i>Rheumatology</i> , 2021, 60, SI68-SI76.	0.9	24
28	Rheumatic presentations of Guillain-Barré syndrome as a diagnostic challenge: A case series. <i>Joint Bone Spine</i> , 2021, 88, 105144.	0.8	1
29	Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 593-600.	1.6	13
30	COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. <i>Lancet Rheumatology, The</i> , 2021, 3, e419-e426.	2.2	211
31	Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France. <i>Arthritis Research and Therapy</i> , 2021, 23, 188.	1.6	9
32	Digital health, big data and smart technologies for the care of patients with systemic autoimmune diseases: Where do we stand?. <i>Autoimmunity Reviews</i> , 2021, 20, 102864.	2.5	25
33	B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrheumdis-2021-220549.	0.5	18
34	Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. <i>Lancet Rheumatology, The</i> , 2021, 3, e613-e615.	2.2	69
35	Fatigue in Systemic Lupus Erythematosus: An Update on Its Impact, Determinants and Therapeutic Management. <i>Journal of Clinical Medicine</i> , 2021, 10, 3996.	1.0	15
36	Le diagnostic de présentation rhumatologique du syndrome de Guillain-Barré: huit cas. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021, 88, 382-386.	0.0	0

#	ARTICLE	IF	CITATIONS
37	The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand?. <i>Journal of Clinical Medicine</i> , 2021, 10, 243.	1.0	43
38	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	1.1	97
39	Practical management of patients on hydroxychloroquine. <i>Joint Bone Spine</i> , 2021, 88, 105316.	0.8	8
40	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. <i>Lupus Science and Medicine</i> , 2021, 8, e000590.	1.1	31
41	Characterization of auto-immune hepatitis associated with the use of anti-TNF \pm agents: An analysis of 389 cases in VigiBase. <i>Autoimmunity Reviews</i> , 2020, 19, 102460.	2.5	21
42	Answer to Tahri et al. «Retinoid Hyperostosis, an overlooked cause of atypical sacroiliac pain in young patients: A pharmacovigilance survey». <i>Joint Bone Spine</i> 2020. doi: 10.1016/j.jbspin.2020.06.023. <i>Joint Bone Spine</i> , 2020, 87, 523-524.	0.8	0
43	Venous thromboembolism in anti-neutrophil cytoplasmic antibody-associated vasculitis: an underlying prothrombotic condition?. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa056.	0.3	9
44	Towards a practical management of fatigue in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2020, 7, e000441.	1.1	18
45	Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. <i>Rheumatology</i> , 2020, 59, v29-v38.	0.9	80
46	Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: Results of a multicenter open-label prospective study. <i>Autoimmunity Reviews</i> , 2020, 19, 102634.	2.5	14
47	Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties. <i>Rheumatology</i> , 2020, 59, 3622-3632.	0.9	39
48	Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2095997.	1.2	10
49	Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2096926.	1.2	16
50	How and why are rheumatologists relevant to COVID-19?. <i>Joint Bone Spine</i> , 2020, 87, 279-280.	0.8	7
51	Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a need for a more accurate control group?. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrhumdis-2020-217651.	0.5	1
52	Disease-specific quality of life following a flare in systemic lupus erythematosus: an item response theory analysis of the French EQUAL cohort. <i>Rheumatology</i> , 2020, 59, 1398-1406.	0.9	12
53	Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations. <i>Lupus Science and Medicine</i> , 2020, 7, e000399.	1.1	11
54	Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014. <i>Autoimmunity Reviews</i> , 2020, 19, 102531.	2.5	79

#	ARTICLE	IF	CITATIONS
55	Is it possible to stop glucocorticoids in systemic lupus?. <i>Joint Bone Spine</i> , 2020, 87, 528-530.	0.8	9
56	10 most important contemporary challenges in the management of SLE. <i>Lupus Science and Medicine</i> , 2019, 6, e000303.	1.1	55
57	Osseous sarcoidosis: A multicenter retrospective case-control study of 48 patients. <i>Joint Bone Spine</i> , 2019, 86, 789-793.	0.8	27
58	Impact of tobacco smoking upon disease risk, activity and therapeutic response in systemic lupus erythematosus: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 102393.	2.5	38
59	Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 504-508.	0.5	54
60	<p>Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 1535-1543.	2.0	47
61	Large-vessel vasculitis diagnosed between 50 and 60&acaronyears: Case-control study based on 183 cases and 183 controls aged over 60&acaronyears. <i>Autoimmunity Reviews</i> , 2019, 18, 714-720.	2.5	12
62	The world-wide burden of musculoskeletal diseases: a systematic analysis of the World Health Organization Burden of Diseases Database. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 844-848.	0.5	184
63	The pipeline of targeted therapies under clinical development for primary Sjàgren's syndrome: A systematic review of trials. <i>Autoimmunity Reviews</i> , 2019, 18, 576-582.	2.5	31
64	The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis. <i>Joint Bone Spine</i> , 2019, 86, 363-368.	0.8	8
65	Rare diseases that mimic Systemic Lupus Erythematosus (Lupus mimickers). <i>Joint Bone Spine</i> , 2019, 86, 165-171.	0.8	31
66	Predictors of fatigue and severe fatigue in a large international cohort of patients with systemic lupus erythematosus and a systematic review of the literature. <i>Rheumatology</i> , 2019, 58, 987-996.	0.9	51
67	Characterizing drug-induced capillary leak syndromes using the World Health Organization VigiBase. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 433-436.	1.5	32
68	Diagnostic performance of temporal artery ultrasound for the diagnosis of giant cell arteritis: a systematic review and meta-analysis of the literature. <i>Autoimmunity Reviews</i> , 2019, 18, 56-61.	2.5	67
69	Systemic lupus erythematosus: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000793.	1.8	66
70	Advances in the treatment of systemic lupus erythematosus: From back to the future, to the future and beyond. <i>Joint Bone Spine</i> , 2019, 86, 429-436.	0.8	24
71	Checkpoint inhibitor-associated immune arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e68-e68.	0.5	27
72	Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212705.	0.5	38

#	ARTICLE	IF	CITATIONS
73	Inflammatory myopathies: A new landscape. <i>Joint Bone Spine</i> , 2018, 85, 23-33.	0.8	31
74	Aortic involvement in relapsing polychondritis. <i>Joint Bone Spine</i> , 2018, 85, 345-351.	0.8	14
75	Validation of the Fautrel classification criteria for adult-onset Still's disease. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 578-585.	1.6	47
76	Targeting interferons and their pathways in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2018, 17, 44-52.	2.5	107
77	Relapsing polychondritis: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000788.	1.8	43
78	Long-Term Dietary Changes after Diagnosis of Rheumatoid Arthritis in Swedish Women: Data from a Population-Based Cohort. <i>International Journal of Rheumatology</i> , 2018, 2018, 1-7.	0.9	6
79	The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials. <i>Autoimmunity Reviews</i> , 2018, 17, 781-790.	2.5	59
80	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.5	268
81	Effect of Corticosteroids and Cyclophosphamide on Sex Hormone Profiles in Male Patients With Systemic Lupus Erythematosus or Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1272-1279.	2.9	28
82	Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 343-351.	2.5	80
83	Takayasu Arteritis and Spondyloarthritis: Coincidence or Association? A Study of 14 Cases. <i>Journal of Rheumatology</i> , 2017, 44, 1011-1017.	1.0	15
84	Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients. <i>Autoimmunity Reviews</i> , 2017, 16, 743-749.	2.5	101
85	Primary thromboprophylaxis with low-dose aspirin and antiphospholipid antibodies: Pro's and Con's. <i>Autoimmunity Reviews</i> , 2017, 16, 1103-1108.	2.5	14
86	Fully automated joint space width measurement and digital X-ray radiogrammetry in early RA. <i>RMD Open</i> , 2017, 3, e000369.	1.8	8
87	Systemic capillary leak syndrome and autoimmune diseases: A case series. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 509-512.	1.6	16
88	Analysis of correlation and causes for discrepancy between quantitative and semi-quantitative Doppler scores in synovitis in rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, 255-262.	0.9	16
89	Long-term efficacy and safety of antitumour necrosis factor alpha treatment in lupus: an open-label study of 15 patients. <i>RMD Open</i> , 2017, 3, e000555.	1.8	20
90	Cutaneous manifestations of Erdheim-Chester disease (ECD): Clinical, pathological, and molecular features in a monocentric series of 40 patients. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 513-520.	0.6	64

#	ARTICLE	IF	CITATIONS
91	Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2016, 15, 203-209.	2.5	50
92	The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 693-699.e3.	0.6	59
93	Antiphospholipid Antibodies in Lupus Nephritis. <i>PLoS ONE</i> , 2016, 11, e0158076.	1.1	26
94	Influence of smoking on the efficacy of antimalarials in cutaneous lupus: A meta-analysis of the literature. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 634-639.	0.6	87
95	Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. <i>Autoimmunity Reviews</i> , 2015, 14, 192-200.	2.5	118
96	Responsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE. <i>Rheumatology</i> , 2015, 54, 940-949.	0.9	58
97	Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature. <i>Autoimmunity Reviews</i> , 2014, 13, 730-735.	2.5	79
98	Successful treatment of combined proliferative and membranous lupus nephritis using a full corticosteroid-free regimen. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 474-475.	0.5	12
99	Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis. <i>Autoimmunity Reviews</i> , 2014, 13, 281-291.	2.5	166
100	Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review. <i>Clinical Rheumatology</i> , 2014, 33, 1209-1215.	1.0	41
101	Prevalence and incidence of systemic lupus erythematosus in France: A 2010 nation-wide population-based study. <i>Autoimmunity Reviews</i> , 2014, 13, 1082-1089.	2.5	106
102	Survival analysis versus event count. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e37-e37.	0.5	1
103	Pathogenesis of relapsing polychondritis: A 2013 update. <i>Autoimmunity Reviews</i> , 2014, 13, 90-95.	2.5	110
104	Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. <i>Blood</i> , 2014, 124, 483-492.	0.6	462
105	The Relapsing Polychondritis Disease Activity Index: Development of a disease activity score for relapsing polychondritis. <i>Autoimmunity Reviews</i> , 2012, 12, 204-209.	2.5	71
106	Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. <i>Blood</i> , 2011, 117, 2783-2790.	0.6	144
107	CNS involvement and treatment with interferon- $\hat{\pm}$ are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. <i>Blood</i> , 2011, 117, 2778-2782.	0.6	331
108	The Systemic Capillary Leak Syndrome: A Case Series of 28 Patients From a European Registry. <i>Annals of Internal Medicine</i> , 2011, 154, 464.	2.0	130

#	ARTICLE	IF	CITATIONS
109	The importance of assessing medication exposure to the definition of refractory disease in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2011, 10, 674-678.	2.5	30
110	Pathogenesis of Takayasu's arteritis: A 2011 update. <i>Autoimmunity Reviews</i> , 2011, 11, 61-67.	2.5	223
111	Exhausted Cytotoxic Control of Epstein-Barr Virus in Human Lupus. <i>PLoS Pathogens</i> , 2011, 7, e1002328.	2.1	111
112	Pulmonary involvement in Erdheim-Chester disease: A single-center study of thirty-four patients and a review of the literature. <i>Arthritis and Rheumatism</i> , 2010, 62, 3504-3512.	6.7	114